Loading
2B
2seventy bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Mar 2024.
2seventy bio, Inc.: what insiders have been doing
This page follows insider dealings at 2seventy bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of 2seventy bio, Inc. in twelve months, the latest record being from 15 May 2025.
Since 2021, the database holds 3 purchases and 61 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
125
Thresholds
n/a
Buy Volume
€3M
3 ops. · all time
Sell Volume
€29M
61 ops. · all time
Who traded when
BuySaleJessica Snow7 sales
Victoria Eatwell3 sales
William D. Baird III3 sales
Nick Leschly2 sales
Kynam Global Healthcare Master Fund, LP1 sale
Marcela Maus V1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$32.6M
Net income-US$49.3M-151.2% margin
Last declaration on 15 May 2025
Declarations125 total
335,964 sharesCommon StockSEC:0001562180-25-003887:0
12,050 sharesCommon StockSEC:0001562180-25-003882:0
12,050 sharesCommon StockSEC:0001562180-25-003912:0
1,002,825 sharesCommon StockSEC:0001562180-25-003879:0
12,050 sharesCommon StockSEC:0001562180-25-003880:0
401,111 sharesCommon StockSEC:0001562180-25-003886:0
17,092 sharesCommon StockSEC:0001562180-25-003881:0
247,230 sharesCommon StockSEC:0001562180-25-003885:0
22,625 shares@ US$5.006.2% of flowCommon Stock, par value $0.0001 per shareSEC:0000919574-25-003264:0
2,592 shares@ US$4.94547.8% of flowCommon StockSEC:0001562180-25-002602:0
2,298 shares@ US$4.94513.8% of flowCommon StockSEC:0001562180-25-002605:0
5,092 shares@ US$4.9454.5% of flowCommon StockSEC:0001562180-25-002603:0
5,953,825 shares@ US$4.9396.5% of flowCommon Stock, par value $0.0001 per shareSEC:0000919574-25-001923:0
1,838 shares@ US$2.79446.6% of flowCommon StockSEC:0001562180-25-000457:0
106,150 shares0Common StockSEC:0001562180-25-000280:0
264,000 shares0Common StockSEC:0001562180-25-000278:0
108,000 shares0Common StockSEC:0001562180-25-000279:0
5,000 shares@ US$2.794417.9% of flowCommon StockSEC:0001562180-25-000246:2
31,718 shares@ US$2.935917.8% of flowCommon StockSEC:0001562180-25-000243:0
1,013 shares@ US$2.935911.8% of flowCommon StockSEC:0001562180-25-000244:0
85,978 shares@ US$2.93594.9% of flowCommon StockSEC:0001562180-25-000245:0
1,000 shares@ US$2.93593.8% of flowCommon StockSEC:0001562180-25-000246:0
763 shares@ US$2.77850.4% of flowCommon StockSEC:0001562180-25-000243:1
892 shares@ US$2.77850.0% of flowCommon StockSEC:0001562180-25-000245:1
25 of 125 declarations
About 2seventy bio, Inc.
2seventy bio, Inc. (ticker: TSVT) is a U.S.-based biotechnology company listed on the NASDAQ in the United States. The company operates in advanced cell and gene therapy, with a historical focus on oncology and, more specifically, transformative cancer treatments. 2seventy bio was created in 2021 through a spin-off from bluebird bio, giving it an independent platform dedicated to CAR-T and related next-generation therapeutic approaches. Its headquarters are in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the U.S.
The company’s business has narrowed materially over the past few quarters. While 2seventy bio previously maintained a broader research pipeline across oncology and adjacent areas, management has reallocated resources toward ABECMA® (idecabtagene vicleucel, or ide-cel), its BCMA-targeted CAR-T therapy for multiple myeloma. In the United States, ABECMA is jointly developed and commercialized with Bristol Myers Squibb under a co-development, co-promotion, and profit-sharing arrangement. Outside the United States, Bristol Myers Squibb retains sole responsibility for manufacturing and commercialization. As a result, ABECMA has become the company’s core strategic and financial asset.
Read moreShow less
From a competitive standpoint, 2seventy bio operates in a highly capital-intensive and scientifically demanding segment, where the competitive landscape is shaped by a small number of large oncology-cell-therapy players and by the ability of major pharmaceutical companies to fund manufacturing, commercialization, and clinical development at scale. In this environment, the investment case for TSVT has been closely tied to ABECMA’s clinical differentiation, market uptake, and the durability of its role in multiple myeloma therapy relative to other biologics and cell therapies.
Recent milestones have been significant. During 2024, the company continued its strategic simplification by divesting portions of its R&D portfolio, including assets transferred to Regeneron, and by concentrating almost entirely on ABECMA. In 2025, 2seventy bio announced a definitive merger agreement under which Bristol Myers Squibb would acquire all outstanding shares for $5.00 per share in an all-cash transaction, underscoring the strategic importance of the company’s principal asset to its partner. For investors, TSVT should be viewed as a specialized NASDAQ-listed U.S. biotech story whose profile is driven by commercial execution, partnership economics, and transaction news rather than by a broad diversified pipeline.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
